Global Differences In Clinical Data Release Policies Cause Headaches For Sponsors
A company could find itself having to create up to five different versions of its clinical study report because of the differences in regulatory policies for publishing clinical data, delegates at the recent DIA Europe 2018 conference heard.
You may also be interested in...
The US FDA commissioner called for enhancements to postmarketing data collection and analysis for generic drugs.
After 10 years in the making, draft legislation for modernizing how medicines and medical devices are regulated in New Zealand has been introduced in parliament for debate.
Patent applicants are being given an extra two months to equip themselves with the tools they will need to use the UPC’s electronic case management system.